Global investment firm The Carlyle Group has agreed to acquire the rapidly growing life sciences tools company Unchained Labs for $435 million, in partnership with its management team, from Novo Holdings A/S, Canaan Partners and TPG Biotech. Equity capital for the investment came from Carlyle Partners VII, an $18.5 billion private equity fund that makes majority and strategic minority investments primarily in the U.S. in targeted industries, including healthcare. The transaction is subject to regulatory approvals and is expected to close in the second quarter 2021.
Founded in 2015 and headquartered in Pleasanton, Calif., Unchained Labs is a life sciences tools company focused on solving problems for biologics and gene therapy researchers. Unchained systems are used by biopharma researchers around the world to analyze and characterize large, complex molecules and to make their research jobs easier. Unchained has 170 employees and expects to generate over $75 million of reve
